Agency for Care Effectiveness - ACE

Directions Website Contact the organization

Agency for Care Effectiveness - ACE ACE is the national health technology assessment (HTA) and clinical guidance agency in Singapore. What We Do


I. II. III. IV.

Welcome to the official page of the Agency for Care Effectiveness (ACE). Established by the Ministry of Health, the Agency for Care Effectiveness (ACE) is the national Health Technology Assessment (HTA) and Clinical Guidance Agency in Singapore. We support providers, patients, and payers make better-informed decisions about patient care. We achieve this by conducting health technology assessments (HTAs), publishing healthcare guidances and providing education. HTA

Established by the Ministry of Health in 2015, we are the national HTA agency in Singapore. We conduct technical evaluations that inform funding decisions for health technologies, and drive their appropriate use by:

• Publishing technology guidances on the clinical effectiveness, safety, and cost-effectiveness of health technologies;
• Conducting value-based pricing negotiations with manufacturers to ensure that prices of patented health technologies are commensurate with the outcomes they deliver for patients and the Singapore health system;
• Tracking utilisation and outcomes related to funded health technologies to study the impact of funding decisions;
• Developing and implementing adoption strategies within public healthcare institutions to drive uptake of technology guidances. Clinical Guidance

We develop and publish clinical guidances that provide concise, evidence-based recommendations to inform specific areas of clinical practice. Healthcare Professional Education

We assist healthcare professionals to apply the best available evidence in their practice through collaborative continuing professional education. Healthcare Consumer Education

We provide information and tools for patients and caregivers to help them find out more about different medical conditions and treatment options, and to take part in shared decision-making with their clinicians about their healthcare needs. Find out more about our work at https://www.ace-hta.gov.sg/campaign/

-

Social Media Terms of Use

We encourage all visitors on our page to start conversations and share with us your thoughts, suggestions, and comments, if any. While we welcome constructive discussions, and want everyone’s experience to be positive, please note that any offensive posts or comments will be removed, and users that repeatedly breach the terms of use may also be blocked from this page. As social media is not a platform for clinical advice – please get in touch with your pharmacist or doctor regarding medical queries. Out of respect for users of our page, ACE reserves the right to remove any comments or posts of the following nature:
- Abusive, vulgar, obscene, violent or defamatory language
- Hateful or discriminatory remarks towards any specific groups or individuals
- Advertising, promotion or endorsement of any products, services or brands
- Fraudulent, inaccurate, non-evidence based information, including spam
- Violation of any copyright, contains proprietary or personal information (email addresses, phone numbers, account numbers etc.)
- Any other comments or posts that breach Facebook’s Term of Service of Community Standards.

23/10/2026

ACE conducts technical evaluations of health technologies, such as drugs, vaccines and medical devices, to inform the Ministry of Health (MOH) advisory committees when they make funding recommendations.

From now till 13 November 2026, patients, carers and representatives from patient or voluntary organisations can submit applications to suggest which health technologies ACE should evaluate for funding consideration.

Read our factsheet to learn more about how patients can be involved and contact your patient organisation for an application form: go.gov.sg/ace-patientfactsheet

22/10/2026

ACE and the Health Sciences Authority (HSA) have jointly developed a patient factsheet on biosimilars - and there's a lot to know!

Did you know that biosimilars are safe and effective medicines that have been used around the world for almost 20 years to treat a wide range of conditions?

In Singapore, selected biosimilars are subsidised as they provide the same therapeutic benefits as the reference biologics while offering good value for money, making them more affordable.

Learn more about biosimilars and the subsidised options available here: https://go.gov.sg/aceli448

20/10/2026

This World Osteoporosis Day, we're highlighting injectable treatment options for adults with osteoporosis.

Osteoporosis is a condition where bones lose minerals faster than the body can replace them, making them weak and fragile. This increases the risk of fractures, most commonly at the hip, spine, and upper limbs.

While adopting a healthy lifestyle can help strengthen bones and reduce the risk of fractures, some patients may also require medication to manage their condition.

ACE's patient factsheet, Injectable Treatments for Osteoporosis, provides information on:
How to reduce the risk of osteoporosis and fractures
Available injectable treatments and their effectiveness
Subsidised treatment options for eligible patients

đź“– Read our patient factsheet to find out more: https://go.gov.sg/factsheet-osteo

12/10/2026

📢 The September 2026 issue of ACE Consumer Engagement and Education (CEE) Updates is now online!

Highlights include:
🌏 Our latest patient involvement activities, including our contributions at the 13th HTAsiaLink 2026 Conference, where we shared Singapore’s experience in patient involvement in HTA and how patient perspectives have informed HTA for rare conditions.

đź“š New and updated patient educational resources, featuring patient factsheets, plain English summaries and our updated patient glossary.

Read the September issue of CEE Updates: go.gov.sg/sep-cee-updates

07/10/2026

ACE conducts technical evaluations of health technologies, such as drugs, vaccines and medical devices, to inform the Ministry of Health (MOH) advisory committees when they make funding recommendations.

From now till 13 November 2026, patients, carers and representatives from patient or voluntary organisations can submit applications to suggest which health technologies ACE should evaluate for funding consideration.

Read our factsheet to learn more about how patients can be involved and contact your patient organisation for an application form: go.gov.sg/ace-patientfactsheet

02/10/2026

Every person's experience of living with a condition is different. 👤

The lived experiences of patients and carers can help inform ACE’s technical reviews of health technologies.

Download our Quick Tips factsheet to learn how patients can provide meaningful input into ACE's work: go.gov.sg/ace-quicktips

29/09/2026

Some heart conditions don't present with obvious symptoms.

This World Heart Day, we’re shining a light on ATTR-CM (transthyretin amyloid cardiomyopathy), an underdiagnosed, rare and progressive condition that may eventually lead to heart failure.

Following ACE’s health technology assessment and value-based pricing negotiations, the MOH Drug Advisory Committee (DAC) has recommended two treatment options for ATTR-CM to be subsidised under the Medication Assistance Fund (MAF), improving access for eligible patients in Singapore.

If you have concerns about your heart health, speak to your doctor.
Learn more in ACE's guidance.

Tafamidis for ATTR-CM: go.gov.sg/guidance-tafamidis
Vutrisiran for ATTR-CM: go.gov.sg/guidance-vutrisiran

14/09/2026

ACE’s Annual Call for Topics is now open! Suggest a health technology for evaluation.

Patients, carers and representatives from patient or voluntary organisations can suggest health technologies, such as drugs, vaccines and medical devices, for ACE to evaluate for funding consideration by MOH advisory committees.

Find out how to suggest a health technology in our factsheet: https://go.gov.sg/ace-patientfactsheet

Submissions close 13 November 2026.

08/07/2026

Have you ever come across a healthcare-related term in our educational resources that you were unfamiliar with?

Our updated Patient Glossary provides simple definitions to help patients and carers better understand technical terms commonly used in ACE’s work. 📖

Find out more here: https://go.gov.sg/acefb321

ACE and the Health Sciences Authority (HSA) have jointly developed a patient factsheet on biosimilars - and there's a lo...
30/06/2026

ACE and the Health Sciences Authority (HSA) have jointly developed a patient factsheet on biosimilars - and there's a lot to know!

Did you know that biosimilars are safe and effective medicines that have been used around the world for almost 20 years to treat a wide range of conditions?

In Singapore, selected biosimilars are subsidised as they provide the same therapeutic benefits as the reference biologics while offering good value for money, making them more affordable.

Learn more about biosimilars and the subsidised options available here: https://go.gov.sg/acefb320

Address

College Of Medicine Building, 16 College Road
Singapore
169854

Website

Alerts

Be the first to know and let us send you an email when Agency for Care Effectiveness - ACE posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Organization

Send a message to Agency for Care Effectiveness - ACE:

Shortcuts

Share

Category